Currently we are investigating two lead drug candidates, BAIT719 and BAIT628, which have completed in-vivo safety studies and are in the early stages of in-vivo efficacy studies for mouse MDR metastatic prostate and triple negative breast cancers. If successful, we envision these therapeutics will have wide ranging efficacy in MDR cancers that rely upon drug efflux to persist.
Learn More: Download the full PDF overview